FDA trying to remover reformulate mucous thinning drugs and 2021 NIH study concerning mucous thinning and treatments.
We hypothesize that the drugs targeting elevated mucins or else implementing better ways to remove excess mucus clogs in airways can improve pulmonary complications in COVID-19 patients.
Another study showed that our immune system recognizes SARS CoV2 as an allergen and establishes an allergic immunity against the virus. This stimulates respiratory mucosal sensitivity and activation of SOX2 gene which leads to goblet cell hyperplasia and mucus hypersecretion as same as other allergic and inflammatory diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440041/